Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-07

Metabolic correction of hepatoerythropoietic porphyria by retrovirus- mediated gene transfer

Objetivo



Hepatoerytropoietic porphyria (HEP) is an inherited metabolic disorder characterised by the accumulation of porphyrins resulting from a deficiency in uroporphyrinogen decarboxylase (UROD). This autosomal recessive disorder has been chosen as a model of hematopoietic disease amenable to gene therapy. The disease is severe, starting early in infancy with no specific treatment and gene therapy would represent a great therapeutc improvement. A gene transfer strategy in hematopoiefic cells using retoviral vectors is proposed.
As first step, the efficiency of the viral constructs is tested on human fibroblasts and lymphoblastoid cells which are easy to obtain. At the next step gene transfer is performed in hematopoietic cells obtained from peripheral blood. In the different target cells, the integration of proviral sequences and their expression is checked in short term and long term cultures. In UROD deficient cells, the metabolic correction is analysed in terms of UROD activity and porphyrin accumulation. Finally, the most appropiate viral construct will be used further, ideally in an animal model of the disease, before the design of a human gene therapy clinical protocol.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

Datos no disponibles

Régimen de financiación

RGI - Research grants (individual fellowships)

Coordinador

Université de Bordeaux II
Aportación de la UE
Sin datos
Dirección
146,Rue Léo Saignat
33076 Bordeaux
Francia
Coste total
Sin datos

Participantes (1)